Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05413018




Registration number
NCT05413018
Ethics application status
Date submitted
25/05/2022
Date registered
9/06/2022
Date last updated
1/10/2024

Titles & IDs
Public title
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Scientific title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine (CC-486) Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Chinese Patients With Acute Myeloid Leukemia in Complete Remission
Secondary ID [1] 0 0
CA055-006
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Leukemia, Myeloid, Acute 0 0
Condition category
Condition code
Cancer 0 0 0 0
Leukaemia - Acute leukaemia
Cancer 0 0 0 0
Leukaemia - Chronic leukaemia
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma
Cancer 0 0 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - CC-486
Other interventions - Placebo

Experimental: CC-486/Oral Azacitidine Administration -

Placebo comparator: Placebo Administration -


Treatment: Drugs: CC-486
Specified dose on specified days

Other interventions: Placebo
Specified dose on specified days
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Relapse-free survival (RFS)
Timepoint [1] 0 0
Up to 30 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
Up to approximately 42 months
Secondary outcome [2] 0 0
Time to relapse
Timepoint [2] 0 0
Up to approximately 30 months
Secondary outcome [3] 0 0
Time to discontinuation of treatment
Timepoint [3] 0 0
Up to approximately 42 months
Secondary outcome [4] 0 0
Number of participants with adverse events (AEs)
Timepoint [4] 0 0
Up to approximately 42 months
Secondary outcome [5] 0 0
Number of participants with physical examination abnormalities
Timepoint [5] 0 0
Up to approximately 42 months
Secondary outcome [6] 0 0
Number of participants with vital sign abnormalities
Timepoint [6] 0 0
Up to approximately 42 months
Secondary outcome [7] 0 0
Number of participants with clinical laboratory abnormalities
Timepoint [7] 0 0
Up to approximately 42 months
Secondary outcome [8] 0 0
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-t))
Timepoint [8] 0 0
Up to 8 weeks
Secondary outcome [9] 0 0
Maximum observed plasma concentration (Cmax)
Timepoint [9] 0 0
Up to 8 weeks
Secondary outcome [10] 0 0
Time of maximum observed concentration (Tmax)
Timepoint [10] 0 0
Up to 8 weeks
Secondary outcome [11] 0 0
Terminal elimination half-life (T1/2)
Timepoint [11] 0 0
Up to 8 weeks
Secondary outcome [12] 0 0
Minimal/measurable residual disease (MRD) assessment by flow cytometric analysis of hematopoietic cell immunophenotypes
Timepoint [12] 0 0
Up to approximately 30 months
Secondary outcome [13] 0 0
Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale
Timepoint [13] 0 0
Up to approximately 30 months
Secondary outcome [14] 0 0
EQ-5D-5L scale
Timepoint [14] 0 0
Up to approximately 30 months
Secondary outcome [15] 0 0
Visual analog scale (VAS)
Timepoint [15] 0 0
Up to approximately 30 months
Secondary outcome [16] 0 0
Healthcare Resource Utilization (HRU): Rate of Hospital Events Per Year
Timepoint [16] 0 0
Up to approximately 30 months
Secondary outcome [17] 0 0
Healthcare Resource Utilization (HRU): Number of Medications
Timepoint [17] 0 0
Up to approximately 30 months
Secondary outcome [18] 0 0
Healthcare Resource Utilization (HRU): Rate of Clinic Visits Per Year
Timepoint [18] 0 0
Up to approximately 30 months
Secondary outcome [19] 0 0
Healthcare Resource Utilization (HRU): Rate of Medical/Diagnostic Events Per Year
Timepoint [19] 0 0
Up to approximately 30 months
Secondary outcome [20] 0 0
Healthcare Resource Utilization (HRU): Number of Treatments for AEs Per Year
Timepoint [20] 0 0
Up to approximately 30 months

Eligibility
Key inclusion criteria
* Newly diagnosed, histologically confirmed de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML)
* Eastern cooperative oncology group performance status of 0, 1, or 2
* Has undergone induction therapy with intensive chemotherapy with or without consolidation therapy
* Must have achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) status within 6 months (+/- 7 days) prior to starting study therapy
Minimum age
55 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Suspected or proven acute promyelocytic leukemia or acute myeloid leukemia with previous hematologic disorder such as chronic myeloid leukemia or myeloproliferative neoplasms, excluding myelodysplastic syndromes and chronic myelomonocytic leukemia
* Candidate for allogeneic bone marrow or stem cell transplant at screening
* Have achieved CR/CRi following therapy with hypomethylating agents
* AML associated with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) karyotypes or molecular evidence of such translocations
* Proven central nervous system leukemia
* Prior bone marrow or stem cell transplantation

Other protocol-defined inclusion/exclusion criteria apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
19/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2026
Actual
Sample size
Target
78
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
China
State/province [1] 0 0
Anhui
Country [2] 0 0
China
State/province [2] 0 0
Beijing
Country [3] 0 0
China
State/province [3] 0 0
CQ
Country [4] 0 0
China
State/province [4] 0 0
Guangdong
Country [5] 0 0
China
State/province [5] 0 0
Hebei
Country [6] 0 0
China
State/province [6] 0 0
Jiangsu
Country [7] 0 0
China
State/province [7] 0 0
Liaoning
Country [8] 0 0
China
State/province [8] 0 0
Shanghai
Country [9] 0 0
China
State/province [9] 0 0
Shanxi
Country [10] 0 0
China
State/province [10] 0 0
Sichuan
Country [11] 0 0
China
State/province [11] 0 0
SN
Country [12] 0 0
China
State/province [12] 0 0
Tianjin
Country [13] 0 0
China
State/province [13] 0 0
Xinjiang
Country [14] 0 0
China
State/province [14] 0 0
Zhejiang
Country [15] 0 0
China
State/province [15] 0 0
Changchun
Country [16] 0 0
China
State/province [16] 0 0
Changsha
Country [17] 0 0
China
State/province [17] 0 0
Ganzhou
Country [18] 0 0
China
State/province [18] 0 0
Guangzhou
Country [19] 0 0
China
State/province [19] 0 0
Hangzhou
Country [20] 0 0
China
State/province [20] 0 0
Harbin
Country [21] 0 0
China
State/province [21] 0 0
Jinan
Country [22] 0 0
China
State/province [22] 0 0
Kunming
Country [23] 0 0
China
State/province [23] 0 0
Lanzhou
Country [24] 0 0
China
State/province [24] 0 0
Nanchang
Country [25] 0 0
China
State/province [25] 0 0
Nanjing
Country [26] 0 0
China
State/province [26] 0 0
Soochow
Country [27] 0 0
China
State/province [27] 0 0
Zhangzhou City
Country [28] 0 0
China
State/province [28] 0 0
Zhengzhou

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bristol-Myers Squibb
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Bristol-Myers Squibb
Address 0 0
Bristol-Myers Squibb
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT05413018